sponsored
New shingles vaccine gets preferential recommendation from ATAGI and NCIRS
But it’s also more expensive than the incumbent
This educational activity was developed by ADG at the request of and with funding from GSK.
Australia’s newest shingles vaccine is now “the preferred zoster vaccine” for adults 50 years and over, according to updated guidance from the National Centre for Immunisation Research and Surveillance (NCIRS) and the Australian Technical Advisory Group on Immunisation (ATAGI).
The guidance states Shingrix (recombinant varicella zoster virus glycoprotein E antigen - AS01B
